EMR-C VS EMR-S in Colonic Lateral Spreading Tumors Treatment (LST) (LST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03498664|
Recruitment Status : Unknown
Verified January 2019 by Mario Marini, Azienda Ospedaliera Universitaria Senese.
Recruitment status was: Recruiting
First Posted : April 17, 2018
Last Update Posted : January 11, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
"Lateral Spreading Tumors" (LSTs) are dysplastic lesions whose protrusion within the lumens the colon is not more than twice as compared to the surrounding non-dysplastic mucosa.
They can be divided into two groups:
Granular type (LST-G) and Non Granular type (LST-NG) Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are currently the most used techniques to resect this type of lesions. Compared to other methods of tissue ablation, EMR allows to carry out the histological evaluation of the resected fragments and ESD of the lesion in toto ("en bloc") EMR is currently the most used technique for removal of LST, but for lesions of ≥ 30 mm the resection is performed "piecemeal", i.e. fragmentary. This can compromise an adequate histological evaluation of the lateral and deep margins of the lesion.
Colonic EMR (EMR-S) is usually performed using a polypectomy snare, after lifting the lesion from the underlying layers with a submucosal injection of liquid (EMR standard or "inject-and-cut"). The aspiration of the lesion inside a plastic cap preloaded on the tip of the colonoscope ("cap-assisted EMR" - EMR-C) is almost exclusively used for the treatment of gastric and esophageal lesions. Its use for lesions of the colon and duodenum has been reported in limited experiences The principal aim of this study is to evaluate the efficacy and the safety of the EMR-C for the removal of large colonic LST-G and LST-NG, comparing it with EMR-S.
|Condition or disease||Intervention/treatment||Phase|
|Endoscopic Mucosal Resection||Device: cap for mucosectomy Device: standard snare for polypectomy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||"Cap-assisted" Endoscopic Mucosal Resection vs Standard "Inject and Cut" Endoscopic Mucosal Resection for Large Colonic "Lateral Spreading Tumors" Treatment: a Randomized Multicentric Study.|
|Actual Study Start Date :||March 15, 2018|
|Estimated Primary Completion Date :||September 15, 2019|
|Estimated Study Completion Date :||September 15, 2019|
Experimental: EMR-C group
A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.
After submucosal injection, the cap will be applied against the lesion which will be aspirated by "controlled suction", avoiding excessive protrusion of tissue in order not to trap the muscular layer.
The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan).
Device: cap for mucosectomy
endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
Active Comparator: EMR-S group
The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
Device: standard snare for polypectomy
endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
- Proportion of patients with residual lesions within 12 months. [ Time Frame: within 12 months ]
Patients with non invasive lesions will undergo follow-up colonoscopies at 3, 6, 12 months and thereafter annually after both EMR-C and EMR-S..
The presence of adenomatous tissue endoscopically visible at follow-up colonoscopies within the first year from EMR will be considered as residual lesion.
- Proportion of patients with recurrence at 12 months. [ Time Frame: at 12 months ]The presence of adenomatous tissue endoscopically visible after two previous negative colonoscopies will be defined as recurrence. "
- Proportion of patients with early complications within 48 hours and late complications after 48 hours from both endoscopic procedures. [ Time Frame: at the time of the procedure, within 48 hours, within 12 months ]
Complications are defined as:
intraprocedural early: within 48 hours; late: after 48 hours from the endoscopic procedure;
Type of complications:
Bleeding (intraprocedural, loss of blood from rectum; Perforation (documented with the presence of free air in abdomen by RX and/or CT); Post polipectomy syndrome (abdominal pain with or without fever, without any free air in abdomen reported by radiological investigations)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients ≥18 years Colonic LST-G/NG () ≥ 30 mm in size. Patients able to undergo all follow up procedures as indicated in the protocol and to provide written informed consent, at least 48 hours before the intervention (reasoned consent).
- Presence of sessile polyps Non polypoid lesions 0-III according to Paris Classification Lesions with suspicion of malignancy (rigidity, non-lifting lesions, mucosal fragility, ulceration) Patients unable to provide informed consent Patients with coagulopathy and INR >1.5 (not corrected with replacement therapy, such as enoxaparin).
Patients who have undergone previous attempt of lesion resection (residual disease, local recurrence).
Patients with histological diagnosis of submucosal invading neoplasia who will be sent to surgery and excluded from follow-up.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03498664
|Contact: Antonella De Ceglie, MDemail@example.com|
|Contact: Mario Marini, MDfirstname.lastname@example.org|
|Siena, Italy, 53100|
|Contact: Mario Marini, MR +393494789809 email@example.com|
|Sub-Investigator: Massimo Conio, MD|
|Sub-Investigator: Antonella De Ceglie, MD|
|Sub-Investigator: Raffaele Manta, MD|
|Principal Investigator:||Mario Marini, MD||Gastroenterology and Operative Endoscopy Unit, Santa Maria Alle Scotte Hospital, Siena, Italy.|
|Study Chair:||Massimo Conio, MD||ASL 1 imperiese|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Mario Marini, MD, Director of Gastroenterology and Operative Endoscopy Unit, Santa Maria Alle Scotte Hospital, Siena, Italy., Azienda Ospedaliera Universitaria Senese|
|Other Study ID Numbers:||
|First Posted:||April 17, 2018 Key Record Dates|
|Last Update Posted:||January 11, 2019|
|Last Verified:||January 2019|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
EMR-C; EMR-S; LST